- Benzinga•2 days ago
Kamada Ltd (NASDAQ: KMDA ) disclosed favorable top-line results of its second stage trial on inhaled Alpha-1 Antitrypsin that met primary endpoint. The study is for the treatment of Alpha-1 Antitrypsin ...
- GlobeNewswire•2 days agoKamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency
Company’ s Inhaled AAT Demonstrated Significant Increase in Endothelial Lining Fluid Inhibitory Capacity. Study Results Also Showed that Inhaled AAT is the Most Efficient Way of Delivering Therapeutic ...
- Insider Monkey•22 days ago
So we just learnt that development stage biotech company Kamada Ltd (NASDAQ:KMDA) is set to put out topline from a phase II in antitrypsin deficiency before the end of this quarter, and intends to file a biologics licensing application (BLA) with the FDA any time now. It’s going to be a busy couple of months […]
Kamada Ltd. (KMDA.TA)
Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
|Bid||1,829.00 x 346500|
|Ask||1,830.00 x 57900|
|Day's Range||1,780.00 - 1,854.00|
|52wk Range||13.03 - 1,854.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-8,719.05|
|Avg Vol (3m)||54,875|
|Dividend & Yield||N/A (N/A)|